Acifran: a double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients.

Area of Science:

• Cardiology
• Pharmacology
• Metabolic Disorders

Background:

• Type IIa hyperlipoproteinemia is characterized by elevated low-density lipoprotein (LDL) cholesterol.
• Effective management of hyperlipoproteinemia is crucial for reducing cardiovascular risk.

Purpose of the Study:

• To evaluate the efficacy and safety of acifran in treating Type IIa hyperlipoproteinemia.
• To assess the impact of acifran on plasma lipid and lipoprotein concentrations.

Main Methods:

• A 12-week, double-blind, placebo-controlled study involving 14 Type IIa hyperlipoproteinemic patients.
• Patients received acifran (100 mg or 300 mg t.i.d.) or placebo.
• Fasting plasma lipid and lipoprotein levels were measured at baseline, week 8, and week 12.

Main Results:

• Acifran significantly reduced LDL cholesterol and the LDL/HDL ratio, while increasing HDL cholesterol at week 8.
• The 300 mg t.i.d. dose of acifran also showed a significant reduction in triglycerides and an increase in HDL cholesterol by week 12.
• No apparent relationship was observed between lipid changes and acifran dose or duration, except for triglycerides.

Conclusions:

• Acifran is a safe and effective treatment for Type IIa hyperlipoproteinemia.
• Acifran demonstrates significant improvements in key lipid parameters, including LDL cholesterol, HDL cholesterol, and triglycerides.